|Bid||45.38 x N/A|
|Ask||45.39 x N/A|
|Day's range||45.13 - 45.49|
|52-week range||31.03 - 46.53|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||14.55|
|Earnings date||02 Nov 2021|
|Forward dividend & yield||0.88 (1.99%)|
|Ex-dividend date||25 May 2021|
|1y target est||N/A|
German healthcare group Fresenius raised 2021 targets though it saw a weaker third quarter, saying progress on its cost-cutting plan should offset troubles at its dialysis unit. The COVID-19 pandemic has affected healthcare groups in different ways as demand for coronavirus-related products and services coincided with the evolution of new coronavirus variants and higher rates of patient deaths. Fresenius said that while it earlier expected lower pandemic effects in late 2021, new coronavirus variants and exposure to high-risk patients at its dialysis unit Fresenius Medical Care could threaten those assumptions in the third quarter.
(Bloomberg) -- Chinese pharmaceutical group Creat Group Corp. is drawing interest from a mix of private equity firms and strategic suitors as it explores a sale of its blood-plasma supply businesses in Germany and the U.K., according to people familiar with the matter.Advent International Corp. and Bain Capital have teamed up to bid for Creat’s stakes in Biotest AG and Bio Products Laboratory Ltd., the people said. The Chinese owner could seek a valuation of up to $3 billion for the assets, they
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.